Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (November 2022)
18 slides from Health X Platform's investor presentation, Nov 22, 2022
Slide 1: Stock exchange intimation letter for Investor Presentation
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 22‐11‐2022 To To Th
Slide 2: Investor Presentation November 2022
Investor Presentation November 2022
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Key Financial Highlights
Key Financial Highlights Revenue from Operations Gross Profit 6.5% 7.4% +64.1% +87.1% 253.9 18.9 154.7 10.1 Q2FY22 Q2FY23 Q2FY22 Q2FY23 Gross Profit ✓ Gross Profit for Q2FY23 stood at Rs. 18.9 crs. Revenue ✓ Gross Profit margins have increased during the year due to ✓ Revenue for Q2FY23 stood at Rs.
Slide 5: Management Comments
Management Comments Commenting on the results and performance for Q2FY23, Mr. B.L. Mittal, Founder & Executive Chairman said “I am delighted to report that our revenue has grown by 64% (YoY) to Rs. 253.9 crore for the second quarter of FY 2022-23. As we shared in the last quarter, we are expanding o
Slide 6: Q2 FY23 Consolidated Profit & Loss Statement
Q2 FY23 Consolidated Profit & Loss Statement Particulars (Rs. Crs) Q2 FY23 Q2 FY22 Y-o-Y Q1 FY23 Q-o-Q H1 FY23 H1 FY22 Y-o-Y Revenue from Operations 253.9 154.7 64.1% 191.6 32.5% 445.6 324.3 37.4% Cost of Materials Consumed 235.0 144.6 179.4 414.4 301.5 Gross Profit 18.9 10.1 87.1% 12.2 54.9% 31.2 2
Slide 7: Balance Sheet As on 30th Sep 2022
Balance Sheet As on 30th Sep 2022 Equity & Liabilities (Rs. Crs) Sep-22 Mar-22 Assets (Rs. Crs) Sep-22 Mar-22 Property, Plant and Equipment 73.2 57.2 Equity Share Capital 31.8 31.8 Capital Work-in-Progress 4.6 0.4 Other Equity 1142.5 1175.7 Intangibles Assets 0.1 0.1 Total Equity 1,174.3 1,207.5 Goo
Slide 8: Macro Strategy: Focus & Growth
Future Macro Strategy Macro Strategy Focus & Growth ‘Digital Platform of Healthcare’ Pharmacy Wellness Diagnostic Develop Leverage Deliver 3T 2C 3C Team Cash Flow Customer Base Technology Customer Experience Capital Trust Community Wellbeing Health & Happiness
Slide 9: Micro Strategy: B2C Platform, B2B Platform, Genu Path Labs
Micro Strategy Micro Strategy B2C Platform B2B Platform Genu Path Labs • Expand & Grow network of Seller • Expand – PAN India, Accelerate • Expand Diagnostic Network in Eastern Pharmacies – PAN India growth India • Expand fulfilment capabilities – • Leverage scale to Maximise • Leverage consumer bas
Slide 10: Historical Financial Highlights
Historical Financial Highlights
Slide 11: FY22 Financial Highlights
FY22 Financial Highlights Rs. In Crs Revenue Revenue from from Operations Operations Gross Profit Q4 4.5% 8.8% 6.5% Q3 62% Q2 137% 622 Q1 48 540 158 +20% 11 41 132 385 10 141 +5% 12 116 134 8 155 +11% 17 13 103 140 10 5 92 4 134 169 +26% 5 12 13 74 3 FY20 FY21 FY22 FY20 FY21 FY22 Gross Profit Revenu
Slide 12: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Revenue from Operations 623.0 540.0 384.0 215.6 148.3 Cost of Materials Consumed 582.5 492.5 366.9 199.5 140.4 Gross Profit 40.5 47.5 17.1 16.1 7.9 GP % 6.5% 8.8% 4.5% 7.5% 5.3% Employee Benefits
Slide 13: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Equity & Liabilities (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Assets (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 57.2 57.3 60.2 62.7 64.8 Other Equity 1175.7 197.6 214.4 168.6 171.3
Slide 14: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Cash Flow from Operating Activities Profit before Tax 1,109.5 (16.4) (57.6) (41.8) (12.4) Adjustment for Non-Operating Items 1,151.0 (3.2) 4.8 7.8 5.4 Operating Profit before Working Capital Changes
Slide 15: Backed by Globally Acclaimed Investors
Backed by Globally Acclaimed Investors Mitsubishi Corporation Investors Rohto Pharmaceutical Co., Ltd. Health & Happiness
Slide 16: Experienced Board of Directors
Experienced Board of Directors ▪ FCA, FCS and FCM by education and has an experience of ▪ FCA by education and is a seasoned entrepreneur with more than 20 years working as an entrepreneur and a more than 20 years of demonstrated experience in social worker. scaling businesses from scratch. ▪ Areas
Slide 17: Join Us For Prayers
Join Us For Prayers Health & Happiness
Slide 18: Thank You
Company: Thank You Sastasundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh – Company Secretary Email Id : investors@sastasundar.com www.sastasundarventures.com Investor Relations Partner: Orient Capital (a division of Link Group) Payal Dave Rasika Sawant payal.dave@linkintime.co.in
Sastasundar Ventures — Investor Presentation (November 2022) on 6ix